Adc Therapeutics Sa Stock Price, News & Analysis

ADC Therapeutics (NYSE: ADCT), a commercial-stage leader in antibody drug conjugates (ADCs), has announced its participation in two upcoming investor conferences. The company's CEO Ameet Mallik will present at the RBC Capital Markets Global Healthcare Conference on May 21, 2025, from 10:30-10:55 a.m. ET, and at the Jefferies Global Healthcare Conference on June 5, 2025, from 9:55-10:25 a.m. ET. Both presentations will be in a fireside chat format and available via webcast on the company's investor relations website, with replays accessible for approximately 30 days after each event.

The company will also present updated LOTIS-5 safety run-in data evaluating ZYNLONTA plus rituximab combination at EHA2025.

ADC Therapeutics (NYSE: ADCT), a commercial-stage leader in antibody drug conjugates (ADCs), has scheduled its first quarter 2025 financial results conference call and webcast for May 14, 2025, at 8:30 a.m. EDT. The company will present financial results and provide business updates during the call.

Participants can join via toll-free dial-in (1-800-836-8184 for North America and Canada) or through a live webcast available on the company's investor relations website. Pre-registration is recommended 10 minutes before the event. The webcast recording will be accessible for 30 days after the call.

ADC Therapeutics (NYSE: ADCT) presented preclinical data for three exatecan-based antibody drug conjugates (ADCs) at the AACR Annual Meeting 2025. The key highlight was ADCT-242, targeting Claudin-6, which demonstrated potent antitumor activity in ovarian and non-small lung cancer models, with good tolerance up to 150 mg/kg in mice and 40 mg/kg in cynomolgus monkeys.

Additionally, ADCT-241, targeting PSMA, showed promising results in prostate cancer models with synergistic effects when combined with enzalutamide. The third ADC, HuB14-VA-PL2202, targeting ASCT2, exhibited potent antitumor activity in both solid and hematological cancer cell lines with good tolerability in preclinical studies.

ADC Therapeutics (NYSE: ADCT) has granted stock options to two new employees to purchase a total of 128,600 common shares, effective April 1, 2025. The grants, approved by the Company's Compensation Committee under the Inducement Plan, serve as material employment incentives.

The stock options will vest over four years, with 25% vesting on the first anniversary and the remaining vesting monthly at 1/48th of the total shares, contingent on continued employment. The grants were made under NYSE's Listed Company Manual Rule 303A.08's employment inducement exemption.

ADC Therapeutics (NYSE: ADCT) has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference. The company's CEO, Ameet Mallik, will deliver a company overview presentation on Tuesday, April 8, 2025, at 8:00 a.m. ET.

Investors and interested parties can access the live webcast through the Events & Presentations page in the Investors section of ADC Therapeutics' website at ir.adctherapeutics.com. A replay of the presentation will remain available for approximately 30 days following the event.